Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24508343 | 0.88 | HSD11B1 (0.52) | HSD11B1IRAK4 | |
| SCHEMBL359700 | 0.78 | KDM4E (0.57) | HSD11B1 | |
| SCHEMBL21326698 | 0.76 | PDE2A (0.53) | HSD11B1 | |
| SCHEMBL31470548 | 0.72 | SMPD3 (0.44) | HSD11B1IRAK4 | |
| SCHEMBL24767177 | 0.72 | KDM4E (0.43) | HSD11B1IRAK4 | |
| SCHEMBL17080357 | 0.72 | PRKAB2 (0.47) | HSD11B1IRAK4 | |
| SCHEMBL10258993 | 0.72 | KDM4E (0.40) | HSD11B1IRAK4 | |
| SCHEMBL309358 | 0.68 | HSD11B1 (0.57) | HSD11B1IRAK4 | |
| SCHEMBL23657692 | 0.68 | KDR (0.59) | — | |
| Hydrochloric Acid SCHEMBL19030927 | 0.67 | HSD11B1 (0.56) | HSD11B1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4271664-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4259128-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-116669722-A | Interleukin-1 receptor-related kinase (IRAK) degradants and uses thereof | 凯麦拉医疗公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230096599-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885IRAK4 4/4885 |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885IRAK4 4/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885IRAK4 4/4885 |
| US-20230096599-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885IRAK4 4/4885 |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD11B1 2834/4885IRAK4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.